Shares of Merus N.V. (NASDAQ:MRUS) have earned an average rating of “Hold” from the six research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.50.

MRUS has been the subject of a number of recent research reports. Jefferies Group LLC reissued a “buy” rating and set a $31.00 price target on shares of Merus N.V. in a research report on Friday, July 14th. Zacks Investment Research raised shares of Merus N.V. from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th. ValuEngine lowered shares of Merus N.V. from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Royal Bank Of Canada initiated coverage on shares of Merus N.V. in a research report on Thursday, September 14th. They set an “outperform” rating and a $28.00 price target for the company.

A number of institutional investors and hedge funds have recently bought and sold shares of MRUS. Spark Investment Management LLC purchased a new position in shares of Merus N.V. during the 1st quarter valued at approximately $458,000. Renaissance Technologies LLC purchased a new position in shares of Merus N.V. during the 1st quarter valued at approximately $549,000. Victory Capital Management Inc. purchased a new position in shares of Merus N.V. during the 1st quarter valued at approximately $976,000. Iguana Healthcare Management LLC increased its holdings in shares of Merus N.V. by 16.7% during the 1st quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock valued at $4,268,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Merus N.V. during the 1st quarter valued at approximately $29,841,000. 32.16% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Merus N.V. (MRUS) Receives $30.50 Average Price Target from Brokerages” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/12/merus-n-v-mrus-receives-30-50-average-price-target-from-brokerages.html.

Merus N.V. (NASDAQ MRUS) traded down 0.76% on Monday, hitting $20.95. 10,824 shares of the stock traded hands. The firm has a 50-day moving average price of $18.38 and a 200-day moving average price of $18.38. Merus N.V. has a 12 month low of $13.13 and a 12 month high of $33.63. The company’s market capitalization is $406.35 million.

About Merus N.V.

Receive News & Stock Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related stocks with our FREE daily email newsletter.